

# Contents

## Part I What Parp is and What it Does

<b>1 History of the Discovery of Poly (ADP-ribose).....</b>	<b>3</b>
Takashi Sugimura and Sydney Shall	
<b>2 Discovery of the PARP Superfamily and Focus on the Lesser Exhibited But Not Lesser Talented Members.....</b>	<b>15</b>
Eléa Héberlé, Jean-Christophe Amé, Giuditta Illuzzi, Françoise Dantzer and Valérie Schreiber	
<b>3 The Role of PARPs in DNA Strand Break Repair .....</b>	<b>47</b>
Stuart L. Rulten, Françoise Dantzer and Keith W. Caldecott	
<b>4 TIPs: Tankyrase Interacting Proteins .....</b>	<b>79</b>
Susan Smith	
<b>5 PARP and Carcinogenesis .....</b>	<b>99</b>
Junhui Wang, Akira Sato, Hiroaki Fujimori, Yoshio Miki and Mitsuko Masutani	
<b>6 Multitasking Roles for Poly(ADP-ribosyl)ation in Aging and Longevity .....</b>	<b>125</b>
Aswin Mangerich and Alexander Bürkle	

## Part II NAD Catalysis and the Identification of Inhibitors

<b>7 Overview of PARP Inhibitor Design and Optimization .....</b>	<b>183</b>
Dana Ferraris	
<b>8 Structure Based Design of PARP Inhibitors.....</b>	<b>205</b>
Stacie S. Canan	

### **Part III Chemo- and Radiosensitisation in Vitro and in Vivo**

<b>9 Preclinical Chemosensitization by PARP Inhibitors.....</b>	<b>225</b>
David R. Shalinsky, Cherrie K. Donawho, Gerrit Los and Joann P. Palma	
<b>10 Classification of PARP Inhibitors Based on PARP Trapping and Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating Agents .....</b>	<b>261</b>
Junko Murai and Yves Pommier	
<b>11 Radiosensitisation by Poly(ADP-ribose) Polymerase Inhibition .....</b>	<b>275</b>
Charles Fouillade, Alexis Fouquin, Mohammed-Tayyib Boudra, Vincent Favaudon, Vincent Pennaneach and Janet Hall	
<b>12 The Vasoactivity of PARP Inhibitors.....</b>	<b>299</b>
Cian M. McCrudden and Kaye J. Williams	

### **Part IV Synthetic Lethality**

<b>13 Synthetic Lethality with Homologous Recombination Repair Defects .....</b>	<b>315</b>
Helen E. Bryant and Sydney Shall	
<b>14 Targeting Tumour Hypoxia with PARP Inhibitors: Contextual Synthetic Lethality .....</b>	<b>345</b>
Katarzyna B. Leszczynska, Nadya Temper, Robert G. Bristow and Ester M. Hammond	
<b>15 Other Determinants of Sensitivity .....</b>	<b>363</b>
Naoyuki Okita and Atsushi Shibata	
<b>16 Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway .....</b>	<b>381</b>
Jennifer A. Stanley and Eddy S. Yang	
<b>17 Disruption of DNA Repair by Cell Cycle and Transcriptional CDK Inhibition.....</b>	<b>413</b>
Liam Cornell, Neil Johnson and Geoffrey I. Shapiro	
<b>18 Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations.....</b>	<b>431</b>
Kiranjit K. Dhillon and Toshiyasu Taniguchi	

<b>19 PARP Inhibitor Resistance—What Is Beyond BRCA1 or BRCA2 Restoration?</b> .....	453
Guotai Xu, Jos Jonkers and Sven Rottenberg	
 <b>Part V Clinical Status</b>	
<b>20 Introduction to PARPi Clinical Trials and Future Directions</b> .....	475
Ruth Plummer and Yvette Drew	
<b>21 Clinical Trials Investigating PARP Inhibitors as Single Agents</b> .....	487
Sheena Irshad and Andrew Tutt	
<b>22 Clinical Trials of PARP Inhibitors with Chemotherapy</b> .....	511
Ashley K. Clift, Nicholas Coupe and Mark R. Middleton	
<b>23 Combination of PARP Inhibitors with Clinical Radiotherapy</b> .....	533
Ross Carruthers and Anthony J. Chalmers	
<b>24 Biomarkers for PARP Inhibitors</b> .....	553
Charles Dearman, Ricky A. Sharma and Nicola J. Curtin	
 <b>Glossary</b> .....	581
 <b>Index</b> .....	589

PARP Inhibitors for Cancer Therapy

Curtin, N.; Sharma, R. (Eds.)

2015, XIX, 591 p. 108 illus., 85 illus. in color. With online  
files/update., Hardcover

ISBN: 978-3-319-14150-3

A product of Humana Press